Related Experiment Videos
Optimizing primary chemotherapy in ovarian cancer
1Department of Hematology/Medical Oncology (R-35), Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. markmam@ccf.org
Hematology/Oncology Clinics of North America
|September 10, 2003
Summary
Standard chemotherapy for advanced ovarian cancer using platinum and taxane agents shows high response rates in most patients. Future research aims to improve treatments by incorporating novel agents to enhance survival and quality of life.
Area of Science:
- Oncology
- Medical Chemistry
Background:
- Advanced ovarian cancer treatment typically involves platinum and taxane chemotherapy.
- This regimen yields significant response rates in a majority of patients.
Purpose of the Study:
- To summarize the efficacy of current primary chemotherapy for advanced ovarian cancer.
- To outline future directions in treatment development.
Main Methods:
- Review of current treatment protocols for advanced ovarian cancer.
- Analysis of patient response rates and survival data.
Main Results:
- Platinum and taxane chemotherapy (carboplatin/cisplatin and paclitaxel/docetaxel) is standard for advanced ovarian cancer.
- 60-80% of patients show favorable subjective and objective responses.
- A notable subset experiences prolonged disease-free and overall survival.
Conclusions:
- Current chemotherapy demonstrates significant efficacy in advanced ovarian cancer.
- Future research will focus on novel antineoplastic agents to improve outcomes.
- Goals include enhanced biologic activity, improved quality of life, and extended survival.